| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer
|
Bogani, G.
|
|
|
35 |
5 |
p. 414-428
|
artikel
|
| 2 |
Corrigendum to ‘IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications’
|
Burotto, M.
|
|
|
35 |
5 |
p. 482
|
artikel
|
| 3 |
Corrigendum to “Moving towards tissue-agnostic antibody drug conjugates: HER2 expression as the poster child”
|
Abelman, R.
|
|
|
35 |
5 |
p. 481
|
artikel
|
| 4 |
Editorial Board
|
|
|
|
35 |
5 |
p. iii
|
artikel
|
| 5 |
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522☆
|
Pusztai, L.
|
|
|
35 |
5 |
p. 429-436
|
artikel
|
| 6 |
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
|
Sangro, B.
|
|
|
35 |
5 |
p. 448-457
|
artikel
|
| 7 |
Importance of pain management in cancer patients and survivors
|
Bhatt, K.
|
|
|
35 |
5 |
p. 473-474
|
artikel
|
| 8 |
New ADCs bring new questions in EGFR NSCLC and beyond
|
Scott, S.
|
|
|
35 |
5 |
p. 412-413
|
artikel
|
| 9 |
Peritoneal effusion: an uncommon adverse effect of selective RET inhibitors
|
Belli, C.
|
|
|
35 |
5 |
p. 478-480
|
artikel
|
| 10 |
Reply to the Letter to the Editor “Importance of pain management in cancer patients and survivors” by K. Bhatt et al.
|
Di Maio, M.
|
|
|
35 |
5 |
p. 475-476
|
artikel
|
| 11 |
Residual disease post neoadjuvant chemo-immunotherapy in early triple-negative breast cancer: does it help tailor adjuvant treatment?
|
Agostinetto, E.
|
|
|
35 |
5 |
p. 409-411
|
artikel
|
| 12 |
Sensitivity of a blood ctDNA-based multimodal test for the detection of advanced colorectal neoplasms
|
Brenner, H.
|
|
|
35 |
5 |
p. 476-477
|
artikel
|
| 13 |
Table of Contents
|
|
|
|
35 |
5 |
p. i-ii
|
artikel
|
| 14 |
The co-expression of antigen targets as a rationale for ADC combination in urothelial cancer
|
Bertucci, F.
|
|
|
35 |
5 |
p. 477-478
|
artikel
|
| 15 |
Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC
|
Yu, H.A.
|
|
|
35 |
5 |
p. 437-447
|
artikel
|
| 16 |
Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes
|
Olmos, D.
|
|
|
35 |
5 |
p. 458-472
|
artikel
|
Tijdschrift beschrijving